WallStSmart

Gossamer Bio Inc (GOSS)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Gossamer Bio Inc generates 7385% more annual revenue ($55.54M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. GOSS earns a higher WallStSmart Score of 44/100 (D).

GOSS

Hold

44

out of 100

Grade: D

Growth: 6.3Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 1/9Altman Z: -13.82

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GOSS2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
71.5%10/10

Revenue surging 71.5% year-over-year

Debt/EquityHealth
-1.2610/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

GOSS4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$41.07M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : GOSS

The strongest argument for GOSS centers on Revenue Growth, Debt/Equity. Revenue growth of 71.5% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : GOSS

The primary concerns for GOSS are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

GOSS profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

GOSS carries more volatility with a beta of 2.00 — expect wider price swings.

GOSS is growing revenue faster at 71.5% — sustainability is the question.

GOSS generates stronger free cash flow (-39M), providing more financial flexibility.

Bottom Line

GOSS scores higher overall (44/100 vs 24/100) and 71.5% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Gossamer Bio Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?